Evaluation of an intelligent digital platform for population management in cervical cancer screening.

IF 8.4 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Cancer Biology & Medicine Pub Date : 2025-09-29 DOI:10.20892/j.issn.2095-3941.2025.0419

Xinhua Jia, Chen Gao, Xi'ao Da, Jingyi Shi, Mingyang Chen, Rufei Duan, Zhifang Li, Ruimei Feng, Yao Yang, Jiahuan Zhai, Hanyue Ding, Alex Ng, Youlin Qiao

{"title":"Evaluation of an intelligent digital platform for population management in cervical cancer screening.","authors":"Xinhua Jia, Chen Gao, Xi'ao Da, Jingyi Shi, Mingyang Chen, Rufei Duan, Zhifang Li, Ruimei Feng, Yao Yang, Jiahuan Zhai, Hanyue Ding, Alex Ng, Youlin Qiao","doi":"10.20892/j.issn.2095-3941.2025.0419","DOIUrl":null,"url":null,"abstract":"Objective: To describe temporal changes associated with deployment of an optical character recognition (OCR)-enabled One-Identity (One-ID) digital platform for rural cervical cancer screening, focusing on over-screening rates, CIN2+ detection, colposcopy follow-up, and CIN2+ management.Methods: A multi-county pre-post observational study was conducted in six rural counties in Shanxi, Yunnan, and Sichuan Provinces (2021-2024), encompassing 153,978 encounters. The digital platform integrates OCR identity capture, deterministic One-ID linkage, and real-time duplicate alerts. Over-screening proportions before and after digital deployment were compared, changes in CIN2+ detection rate were evaluated, and colposcopy follow-up and CIN2+ management were assessed. Differences were tested with χ2 or Fisher's exact tests.Results: Among 153,978 encounters, the proportion of over-screening decreased from 12.64% in 2023 to 0.17% in 2024 with an absolute reduction of 12.17% (95% CI: 11.94-12.40; P < 0.001). The share of women receiving a first screening within the preceding 3 y increased from 78.3% to 88.2% (P < 0.001). Colposcopy completion improved from 64.1% to 84.9%. The CIN2+ detection rate rose from 0.35% (2021-2023 pooled) to 0.67% in 2024 (P < 0.001) and CIN2+ management completion increased from 56.0% to 76.2% (95% CI: 13.3-27.2; P < 0.001). These improvements were consistent across age groups, counties, and screening strategies.Conclusions: The OCR-enabled One-ID platform substantially reduced over-screening, increased CIN2+ detection rate, and strengthened case follow-up/management, particularly where baseline tracking was weak, supporting scalable digital reinforcement of rural screening programmes.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501891/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2025.0419","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To describe temporal changes associated with deployment of an optical character recognition (OCR)-enabled One-Identity (One-ID) digital platform for rural cervical cancer screening, focusing on over-screening rates, CIN2+ detection, colposcopy follow-up, and CIN2+ management.

Methods: A multi-county pre-post observational study was conducted in six rural counties in Shanxi, Yunnan, and Sichuan Provinces (2021-2024), encompassing 153,978 encounters. The digital platform integrates OCR identity capture, deterministic One-ID linkage, and real-time duplicate alerts. Over-screening proportions before and after digital deployment were compared, changes in CIN2+ detection rate were evaluated, and colposcopy follow-up and CIN2+ management were assessed. Differences were tested with χ² or Fisher's exact tests.

Results: Among 153,978 encounters, the proportion of over-screening decreased from 12.64% in 2023 to 0.17% in 2024 with an absolute reduction of 12.17% (95% CI: 11.94-12.40; P < 0.001). The share of women receiving a first screening within the preceding 3 y increased from 78.3% to 88.2% (P < 0.001). Colposcopy completion improved from 64.1% to 84.9%. The CIN2+ detection rate rose from 0.35% (2021-2023 pooled) to 0.67% in 2024 (P < 0.001) and CIN2+ management completion increased from 56.0% to 76.2% (95% CI: 13.3-27.2; P < 0.001). These improvements were consistent across age groups, counties, and screening strategies.

Conclusions: The OCR-enabled One-ID platform substantially reduced over-screening, increased CIN2+ detection rate, and strengthened case follow-up/management, particularly where baseline tracking was weak, supporting scalable digital reinforcement of rural screening programmes.

查看原文本刊更多论文

宫颈癌筛查人群管理智能数字平台的评价。

目的：描述用于农村宫颈癌筛查的支持光学字符识别（OCR）的One-Identity （One-ID）数字平台部署的时间变化，重点关注过度筛查率、CIN2+检测、阴道镜随访和CIN2+管理。方法：在山西、云南和四川3省6个农村县（2021-2024年）开展多县前后观察研究，共153978人次。该数字平台集成了OCR身份捕获、确定性One-ID链接和实时重复警报。比较数字化部署前后的过筛比例，评估CIN2+检出率的变化，评估阴道镜随访及CIN2+处理情况。差异采用χ2或Fisher精确检验。结果：在153,978次就诊中，过度筛查比例从2023年的12.64%下降到2024年的0.17%，绝对下降12.17% （95% CI: 11.94 ~ 12.40; P < 0.001）。在前3年内接受第一次筛查的妇女比例从78.3%增加到88.2% （P < 0.001）。阴道镜检查完成率从64.1%提高到84.9%。CIN2+检出率从2021-2023年的0.35%上升到2024年的0.67% (P < 0.001)， CIN2+管理完成率从56.0%上升到76.2% （95% CI: 13.3-27.2, P < 0.001）。这些改善在各个年龄组、县和筛查策略中都是一致的。结论：支持ocr的One-ID平台大大减少了过度筛查，提高了CIN2+检出率，并加强了病例随访/管理，特别是在基线跟踪薄弱的情况下，支持可扩展的农村筛查计划的数字化强化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biology & Medicine Medicine-Oncology

CiteScore

9.80

自引率

3.60%

发文量

1143

审稿时长

12 weeks

期刊介绍： Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.